Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

summit therapeutics inc - SMMT

SMMT

Close Chg Chg %
18.92 0.46 2.43%

Closed Market

19.38

+0.46 (2.43%)

Volume: 3.08M

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Trade Now

Company Overview: summit therapeutics inc - SMMT

SMMT Key Data

Open

$18.41

 Day Range

18.40 - 19.85

52 Week Range

13.83 - 36.91

 Market Cap

$14.43B

Shares Outstanding

744.44M

 Public Float

102.98M

Beta

-1.37

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.44

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.63M

  

SMMT Performance

1 Week
 
 16.89%
 
1 Month
 
 28.26%
 
3 Months
 
 10.62%
 
1 Year
 
 11.64%
 
5 Years
 
 215.64%
 

SMMT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔

About summit therapeutics inc - SMMT

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

SMMT At a Glance

Summit Therapeutics, Inc.
601 Brickell Key Drive
Miami, Florida 33131
Phone 1-305-203-2034 Revenue 0.00
Industry Biotechnology Net Income -1,079,586,000.00
Sector Health Technology Employees 265
Fiscal Year-end 12 / 2026
View SEC Filings

SMMT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 20.583
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -11.317
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.002

SMMT Efficiency

Revenue/Employee N/A
Income Per Employee -4,073,909.434
Receivables Turnover N/A
Total Asset Turnover N/A

SMMT Liquidity

Current Ratio 9.869
Quick Ratio 9.869
Cash Ratio 9.779

SMMT Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -181.941
Return on Equity -206.105
Return on Total Capital -158.821
Return on Invested Capital -202.063

SMMT Capital Structure

Total Debt to Total Equity 3.171
Total Debt to Total Capital 3.073
Total Debt to Total Assets 2.781
Long-Term Debt to Equity 2.656
Long-Term Debt to Total Capital 2.575
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Summit Therapeutics Inc - SMMT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - 705.00K
-
Sales Growth
- - -61.03% -100.00%
-
Cost of Goods Sold (COGS) incl D&A
2.51M 2.05M 89.00K 146.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.51M 2.05M 89.00K 146.00K
Depreciation
1.60M 2.05M 89.00K 146.00K
Amortization of Intangibles
- - - 914.00K
-
COGS Growth
- -18.46% -95.66% +64.04%
Gross Income
(1.81M) (2.05M) (89.00K) (146.00K)
Gross Income Growth
- -13.32% +95.66% -64.04%
Gross Profit Margin
- - - -256.60%
-
2022 2023 2024 2025 5-year trend
SG&A Expense
77.49M 87.69M 211.22M 1.09B
Research & Development
52.35M 59.47M 150.78M 537.67M
Other SG&A
25.14M 28.22M 60.44M 556.60M
SGA Growth
-27.24% +13.15% +140.88% +418.09%
Other Operating Expense
- - - -
-
Unusual Expense
- 7.20M 520.92M 15.01M
EBIT after Unusual Expense
(86.51M) (610.65M) (226.31M) (1.09B)
Non Operating Income/Expense
7.60M 11.24M 13.37M 14.84M
Non-Operating Interest Income
1.51M 10.40M 13.47M 15.50M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 4.40M 16.46M 8.69M
Interest Expense Growth
+1,466.19% +274.03% -47.23% -100.00%
Gross Interest Expense
- 4.40M 16.46M 8.69M
Interest Capitalized
- - - -
-
Pretax Income
(83.31M) (615.87M) (221.63M) (1.08B)
Pretax Income Growth
+19.75% -639.30% +64.01% -387.12%
Pretax Margin
- - - -11,816.31%
-
Income Tax
- (4.52M) (946.00K) (313.00K)
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- 4.52M 946.00K 313.00K
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(78.78M) (614.93M) (221.32M) (1.08B)
Minority Interest Expense
- - - -
-
Net Income
(78.78M) (614.93M) (221.32M) (1.08B)
Net Income Growth
+11.08% -680.54% +64.01% -387.81%
Net Margin Growth
- - - -11,174.75%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(78.78M) (614.93M) (221.32M) (1.08B)
Preferred Dividends
- - - -
-
Net Income Available to Common
(78.78M) (614.93M) (221.32M) (1.08B)
EPS (Basic)
-0.4075 -0.9924 -0.308 -1.4439
EPS (Basic) Growth
+57.58% -143.53% +68.96% -368.80%
Basic Shares Outstanding
193.34M 619.65M 718.54M 747.70M
EPS (Diluted)
-0.4075 -0.9924 -0.308 -1.4439
EPS (Diluted) Growth
+57.58% -143.53% +68.96% -368.80%
Diluted Shares Outstanding
193.34M 619.65M 718.54M 747.70M
EBITDA
(76.79M) (87.69M) (211.22M) (1.09B)
EBITDA Growth
+26.66% -14.19% -140.88% -418.09%
EBITDA Margin
- - - -10,891.91%
-

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 31.714
Number of Ratings 17 Current Quarters Estimate -0.299
FY Report Date 06 / 2026 Current Year's Estimate -1.163
Last Quarter’s Earnings -0.285 Median PE on CY Estimate N/A
Year Ago Earnings -1.44 Next Fiscal Year Estimate -1.156
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 13 13 12
Mean Estimate -0.30 -0.29 -1.16 -1.16
High Estimates -0.15 -0.15 -0.60 -0.58
Low Estimate -0.47 -0.43 -1.74 -1.78
Coefficient of Variance -32.34 -34.76 -32.65 -37.23

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 12 12 13
OVERWEIGHT 0 0 0
HOLD 4 4 3
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Summit Therapeutics Inc - SMMT

Date Name Shares Transaction Value
Jan 13, 2026 Bhaskar Anand Chief Accounting Officer 30,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Robert William Duggan Co-Chief Executive Officer; Director 11,232 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Robert F. G. Booth Director 35,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Robert F. G. Booth Director 7,180 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Mahkam Zanganeh Co-Chief Executive Officer; Director 11,232 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Mostafa Ronaghi Director 35,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Jeffrey T. Huber Director 35,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Jeffrey T. Huber Director 9,885 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Kenneth A. Clark Director 35,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Kenneth A. Clark Director 17,796 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Alessandra Cesano Director 35,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Alessandra Cesano Director 3,219 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Yu Xia Director 35,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Summit Therapeutics Inc in the News